

Chad M Thompson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3480264/publications.pdf>

Version: 2024-02-01

68
papers

1,973
citations

236925

25
h-index

276875

41
g-index

68
all docs

68
docs citations

68
times ranked

1902
citing authors

#	ARTICLE	IF	CITATIONS
1	Crypt and Villus Transcriptomic Responses in Mouse Small Intestine Following Oral Exposure to Hexavalent Chromium. <i>Toxicological Sciences</i> , 2022, 186, 43-57.	3.1	1
2	Assessment of Mechanistic Data for Hexavalent Chromium-Induced Rodent Intestinal Cancer Using the Key Characteristics of Carcinogens. <i>Toxicological Sciences</i> , 2021, 180, 38-50.	3.1	12
3	Inhalation cancer risk assessment for environmental exposure to hexavalent chromium: Comparison of margin-of-exposure and linear extrapolation approaches. <i>Regulatory Toxicology and Pharmacology</i> , 2021, 124, 104969.	2.7	4
4	Development of updated RfD and RfC values for medium carbon range aromatic and aliphatic total petroleum hydrocarbon fractions. <i>Journal of the Air and Waste Management Association</i> , 2021, 71, 1-13.	1.9	1
5	A review of mammalian <i>in vivo</i> genotoxicity of hexavalent chromium: implications for oral carcinogenicity risk assessment. <i>Critical Reviews in Toxicology</i> , 2021, 51, 820-849.	3.9	4
6	An adverse outcome pathway for small intestinal tumors in mice involving chronic cytotoxicity and regenerative hyperplasia: a case study with hexavalent chromium, captan, and folpet. <i>Critical Reviews in Toxicology</i> , 2020, 50, 685-706.	3.9	20
7	Assessment of the Mode of Action Underlying the Effects of GenX in Mouse Liver and Implications for Assessing Human Health Risks. <i>Toxicologic Pathology</i> , 2020, 48, 494-508.	1.8	40
8	Exposure to environmentally-relevant concentrations of hexavalent chromium does not induce ovarian toxicity in mice. <i>Regulatory Toxicology and Pharmacology</i> , 2020, 116, 104729.	2.7	8
9	Comparison of threshold of toxicological concern (TTC) values to oral reference dose (RfD) values. <i>Regulatory Toxicology and Pharmacology</i> , 2020, 113, 104651.	2.7	11
10	Using mechanistic information to support evidence integration and synthesis: a case study with inhaled formaldehyde and leukemia. <i>Critical Reviews in Toxicology</i> , 2020, 50, 885-918.	3.9	6
11	An updated mode of action and human relevance framework evaluation for Formaldehyde-Related nasal tumors. <i>Critical Reviews in Toxicology</i> , 2020, 50, 919-952.	3.9	7
12	Comparison of Gene Expression Responses in the Small Intestine of Mice Following Exposure to 3 Carcinogens Using the S1500+ Gene Set Informs a Potential Common Adverse Outcome Pathway. <i>Toxicologic Pathology</i> , 2019, 47, 851-864.	1.8	9
13	Development of an oral reference dose for the perfluorinated compound GenX. <i>Journal of Applied Toxicology</i> , 2019, 39, 1267-1282.	2.8	22
14	Considerations for refining the risk assessment process for formaldehyde: Results from an interdisciplinary workshop. <i>Regulatory Toxicology and Pharmacology</i> , 2019, 106, 210-223.	2.7	19
15	Review of transcriptomic responses to hexavalent chromium exposure in lung cells supports a role of epigenetic mediators in carcinogenesis. <i>Toxicology Letters</i> , 2019, 305, 40-50.	0.8	60
16	Dose-dependence of chemical carcinogenicity: Biological mechanisms for thresholds and implications for risk assessment. <i>Chemico-Biological Interactions</i> , 2019, 301, 112-127.	4.0	29
17	Hexavalent Chromium in Drinking Water. <i>Journal - American Water Works Association</i> , 2018, 110, E22.	0.3	49
18	Integration of mechanistic and pharmacokinetic information to derive oral reference dose and margin-of-exposure values for hexavalent chromium. <i>Journal of Applied Toxicology</i> , 2018, 38, 351-365.	2.8	19

#	ARTICLE	IF	CITATIONS
19	Commentary on New Formaldehyde Studies in Trp53 Haploinsufficient Mice: Further Support for Nonlinear Risks From Inhaled Formaldehyde. <i>Dose-Response</i> , 2018, 16, 155932581877793.	1.6	1
20	Assessment of the mode of action underlying development of forestomach tumors in rodents following oral exposure to ethyl acrylate and relevance to humans. <i>Regulatory Toxicology and Pharmacology</i> , 2018, 96, 178-189.	2.7	5
21	High-Throughput Screening Data Interpretation in the Context of In Vivo Transcriptomic Responses to Oral Cr(VI) Exposure. <i>Toxicological Sciences</i> , 2017, 158, 199-212.	3.1	21
22	Ten factors for considering the mode of action of Cr(VI)-induced gastrointestinal tumors in rodents. <i>Mutation Research - Genetic Toxicology and Environmental Mutagenesis</i> , 2017, 823, 45-57.	1.7	13
23	Benchmark Dose Modeling Estimates of the Concentrations of Inorganic Arsenic That Induce Changes to the Neonatal Transcriptome, Proteome, and Epigenome in a Pregnancy Cohort. <i>Chemical Research in Toxicology</i> , 2017, 30, 1911-1920.	3.3	38
24	Comparison of Toxicity and Recovery in the Duodenum of B6C3F1 Mice Following Treatment with Intestinal Carcinogens Captan, Folpet, and Hexavalent Chromium. <i>Toxicologic Pathology</i> , 2017, 45, 1091-1101.	1.8	15
25	Assessment of the mutagenic potential of hexavalent chromium in the duodenum of big blue [®] rats. <i>Toxicology and Applied Pharmacology</i> , 2017, 330, 48-52.	2.8	25
26	Transcriptomic responses in the oral cavity of F344 rats and B6C3F1 mice following exposure to Cr(VI): Implications for risk assessment. <i>Environmental and Molecular Mutagenesis</i> , 2016, 57, 706-716.	2.2	13
27	Comparison of in vivo genotoxic and carcinogenic potency to augment mode of action analysis: Case study with hexavalent chromium. <i>Mutation Research - Genetic Toxicology and Environmental Mutagenesis</i> , 2016, 800-801, 28-34.	1.7	17
28	Development of linear and threshold no significant risk levels for inhalation exposure to titanium dioxide using systematic review and mode of action considerations. <i>Regulatory Toxicology and Pharmacology</i> , 2016, 80, 60-70.	2.7	15
29	Reevaluation and Classification of Duodenal Lesions in B6C3F1 Mice and F344 Rats from 4 Studies of Hexavalent Chromium in Drinking Water. <i>Toxicologic Pathology</i> , 2016, 44, 279-289.	1.8	15
30	Assessment of the mutagenic potential of Cr(VI) in the oral mucosa of Big Blue [®] transgenic F344 rats. <i>Environmental and Molecular Mutagenesis</i> , 2015, 56, 621-628.	2.2	26
31	A robust method for assessing chemically induced mutagenic effects in the oral cavity of transgenic Big Blue [®] rats. <i>Environmental and Molecular Mutagenesis</i> , 2015, 56, 629-636.	2.2	7
32	Synchrotron-Based Imaging of Chromium and γ -H2AX Immunostaining in the Duodenum Following Repeated Exposure to Cr(VI) in Drinking Water. <i>Toxicological Sciences</i> , 2015, 143, 16-25.	3.1	39
33	Duodenal crypt health following exposure to Cr(VI): Micronucleus scoring, γ -H2AX immunostaining, and synchrotron X-ray fluorescence microscopy. <i>Mutation Research - Genetic Toxicology and Environmental Mutagenesis</i> , 2015, 789-790, 61-66.	1.7	26
34	A chronic oral reference dose for hexavalent chromium-induced intestinal cancer. <i>Journal of Applied Toxicology</i> , 2014, 34, 525-536.	2.8	123
35	Assessment of the mode of action for hexavalent chromium-induced lung cancer following inhalation exposures. <i>Toxicology</i> , 2014, 325, 160-179.	4.2	99
36	High concentrations of hexavalent chromium in drinking water alter iron homeostasis in F344 rats and B6C3F1 mice. <i>Food and Chemical Toxicology</i> , 2014, 65, 381-388.	3.6	23

#	ARTICLE	IF	CITATIONS
37	Assessment of K-Ras mutant frequency and micronucleus incidence in the mouse duodenum following 90-days of exposure to Cr(VI) in drinking water. <i>Mutation Research - Genetic Toxicology and Environmental Mutagenesis</i> , 2013, 754, 15-21.	1.7	35
38	An approach for integrating toxicogenomic data in risk assessment: The dibutyl phthalate case study. <i>Toxicology and Applied Pharmacology</i> , 2013, 271, 324-335.	2.8	16
39	Utilizing toxicogenomic data to understand chemical mechanism of action in risk assessment. <i>Toxicology and Applied Pharmacology</i> , 2013, 271, 299-308.	2.8	47
40	Development of a chronic noncancer oral reference dose and drinking water screening level for sulfolane using benchmark dose modeling. <i>Journal of Applied Toxicology</i> , 2013, 33, 1395-1406.	2.8	14
41	Assessment of the mode of action underlying development of rodent small intestinal tumors following oral exposure to hexavalent chromium and relevance to humans. <i>Critical Reviews in Toxicology</i> , 2013, 43, 244-274.	3.9	66
42	A Genomics-Based Analysis of Relative Potencies of Dioxin-Like Compounds in Primary Rat Hepatocytes. <i>Toxicological Sciences</i> , 2013, 136, 595-604.	3.1	12
43	Duodenal GSH/GSSG Ratios in Mice Following Oral Exposure to Cr(VI). <i>Toxicological Sciences</i> , 2012, 126, 287-288.	3.1	0
44	Assessment of Cr(VI)-Induced Cytotoxicity and Genotoxicity Using High Content Analysis. <i>PLoS ONE</i> , 2012, 7, e42720.	2.5	61
45	Comparison of the Effects of Hexavalent Chromium in the Alimentary Canal of F344 Rats and B6C3F1 Mice Following Exposure in Drinking Water: Implications for Carcinogenic Modes of Action. <i>Toxicological Sciences</i> , 2012, 125, 79-90.	3.1	55
46	Assessment of genotoxic potential of Cr(VI) in the mouse duodenum: An in silico comparison with mutagenic and nonmutagenic carcinogens across tissues. <i>Regulatory Toxicology and Pharmacology</i> , 2012, 64, 68-76.	2.7	15
47	Hexavalent chromium reduction kinetics in rodent stomach contents. <i>Chemosphere</i> , 2012, 89, 487-493.	8.2	34
48	Genome-wide gene expression effects in B6C3F1 mouse intestinal epithelia following 7 and 90 days of exposure to hexavalent chromium in drinking water. <i>Toxicology and Applied Pharmacology</i> , 2012, 259, 13-26.	2.8	45
49	Comparative toxicogenomic analysis of oral Cr(VI) exposure effects in rat and mouse small intestinal epithelia. <i>Toxicology and Applied Pharmacology</i> , 2012, 262, 124-138.	2.8	29
50	A response to a quantitative assessment of the carcinogenicity of hexavalent chromium by the oral route and its relevance to human exposure. <i>Environmental Research</i> , 2011, 111, 468-470.	7.5	5
51	Considerations for the Implausibility of Leukemia Induction by Formaldehyde. <i>Toxicological Sciences</i> , 2011, 120, 230-232.	3.1	5
52	Investigation of the Mode of Action Underlying the Tumorigenic Response Induced in B6C3F1 Mice Exposed Orally to Hexavalent Chromium. <i>Toxicological Sciences</i> , 2011, 123, 58-70.	3.1	81
53	Application of the U.S. EPA Mode of Action Framework for Purposes of Guiding Future Research: A Case Study Involving the Oral Carcinogenicity of Hexavalent Chromium. <i>Toxicological Sciences</i> , 2011, 119, 20-40.	3.1	63
54	Formaldehyde dehydrogenase: Beyond phase I metabolism. <i>Toxicology Letters</i> , 2010, 193, 1-3.	0.8	33

#	ARTICLE	IF	CITATIONS
55	The Ontogeny, Distribution, and Regulation of Alcohol Dehydrogenase 3: Implications for Pulmonary Physiology. <i>Drug Metabolism and Disposition</i> , 2009, 37, 1565-1571.	3.3	18
56	Commentary: mechanistic considerations for associations between formaldehyde exposure and nasopharyngeal carcinoma. <i>Environmental Health</i> , 2009, 8, 53.	4.0	7
57	A lifestage-specific approach to hazard and dose-response characterization for children's health risk assessment. <i>Birth Defects Research Part B: Developmental and Reproductive Toxicology</i> , 2008, 83, 530-546.	1.4	22
58	Uncertainties in Biologically-Based Modeling of Formaldehyde-Induced Respiratory Cancer Risk: Identification of Key Issues. <i>Risk Analysis</i> , 2008, 28, 907-923.	2.7	13
59	Renal clearance parameters for PBPK model analysis of early lifestage differences in the disposition of environmental toxicants. <i>Regulatory Toxicology and Pharmacology</i> , 2008, 51, 66-86.	2.7	49
60	Mechanistic and dose considerations for supporting adverse pulmonary physiology in response to formaldehyde. <i>Toxicology and Applied Pharmacology</i> , 2008, 233, 355-359.	2.8	26
61	Mechanistic Considerations For Formaldehyde-Induced Bronchoconstriction Involving <i>S</i> -Nitrosoglutathione Reductase. <i>Journal of Toxicology and Environmental Health - Part A: Current Issues</i> , 2007, 71, 244-248.	2.3	15
62	Evaluation of physiologically based pharmacokinetic models for use in risk assessment. <i>Journal of Applied Toxicology</i> , 2007, 27, 218-237.	2.8	130
63	Activation of G-Proteins by Morphine and Codeine Congeners: Insights to the Relevance of <i>O</i> - and <i>N</i> -Demethylated Metabolites at μ - and δ -Opioid Receptors. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2004, 308, 547-554.	2.5	84
64	Isolation of Partially Purified P450 2D18 and Characterization of Activity toward the Tricyclic Antidepressants Imipramine and Desipramine. <i>Archives of Biochemistry and Biophysics</i> , 1998, 359, 115-121.	3.0	9
65	The Vesicle Transport Protein Vps33p Is an ATP-binding Protein That Localizes to the Cytosol in an Energy-dependent Manner. <i>Journal of Biological Chemistry</i> , 1998, 273, 15818-15829.	3.4	53
66	Protein Expression, Characterization, and Regulation of CYP4F4 and CYP4F5 Cloned from Rat Brain. <i>Archives of Biochemistry and Biophysics</i> , 1997, 347, 148-154.	3.0	66
67	Barbiturate-induced expression of neuronal nitric oxide synthase in the rat cerebellum. <i>Brain Research</i> , 1997, 754, 142-146.	2.2	15
68	Evaluation of Transcriptomic Responses in Livers of Mice Exposed to the Short-Chain PFAS Compound HFPO-DA. <i>Frontiers in Toxicology</i> , 0, 4, .	3.1	8